Chemotherapy-Induced Neutropenia Treatment Market Size Projected To Reach 0.76 Billion By 2034 With A Cagr Of 5.3%

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Projected Growth of the Chemotherapy-Induced Neutropenia Treatment Market?
Over the past couple of years, the market size for treatment of chemotherapy-induced neutropenia has seen significant enlargement. The market is predicted to soar from $0.59 billion in 2024 to $0.62 billion in 2025, experiencing a compound annual growth rate (CAGR) of 5.7%. Multiple factors have prompted the growth in the historical duration such as the escalation in cancer occurrence rates, the growing uptake of chemotherapy, rise in elderly population, increased hospitalization due to infections, and the broadening of cancer-fighting drug pipelines.

The market for treatment of chemotherapy-induced neutropenia is poised for robust expansion in the years ahead, with projections suggesting a growth to $0.76 billion by 2029, corresponding to a compound annual growth rate of 5.3%. Factors propelling the growth during the forecasted period include heightened demand for specific neutropenia treatments, increased investments in oncological research and development, intensifying focus on outpatient care, wider acceptance of biosimilars, and enhanced consciousness about infection prevention. The forecast period will also witness the rise of several key trends such as the advent of long-lasting granulocyte colony-stimulating factor therapy (G-CSF) agents, growing usage of combined treatments, an increment in preferences for home-centric care solutions, a surge in the approvals for biosimilars, and the integration of digital solutions for health monitoring.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/customise?id=24190&type=smp

What Are the Different Chemotherapy-Induced Neutropenia Treatment Market Segments?
The chemotherapy-induced neutropenia treatment market covered in this report is segmented -

1) By Type: Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy (G-CSF), Granulocyte Transfusion, Other Types
2) By Route of Administration: Subcutaneous, Intravenous
3) By Indication: Solid Tumors, Hematological Malignancies, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Specialty Clinics, Homecare Settings

Subsegments:
1) By Antibiotic Therapy: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics, Prophylactic Antibiotics
2) By Granulocyte Colony-Stimulating Factor Therapy (G-CSF): Filgrastim, Pegfilgrastim, Lenograstim
3) By Granulocyte Transfusion: Allogeneic Granulocyte Transfusion, Autologous Granulocyte Transfusion
4) By Other Types: Antifungal Therapy, Stem Cell Therapy, Immunomodulatory Therapy

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24190&type=smp

What Are the Primary Drivers Shaping the Chemotherapy-Induced Neutropenia Treatment Market?
The escalating prevalence of cancer is predicted to fuel the expansion of the market for treatment of chemotherapy-induced neutropenia in the future. Cancer is a collection of diseases marked by unchecked expansion and dissemination of atypical cells within the body. The surge in cancer incidents can be attributed to an aging population, as the likelihood of cancer development amplifies in older individuals due to a buildup of genetic mutations and a progressive decline in immune system efficacy. Treatment for chemotherapy-induced neutropenia plays a crucial role in cancer management by mitigating infection hazards via immune reinforcement, enabling patients to pursue chemotherapy with minimal disruptions. By curtailing complications, it enhances patient outcomes while improving safety and quality of life. For example, as reported by the Australian Institute of Health and Welfare, a government agency based in Australia, in July 2024, the count of cancer diagnoses in Australia escalated to 160,570 in 2022, up by 3,789 cases from 156,781 in 2021. Hence, the burgeoning prevalence of cancer is propelling the expansion of the chemotherapy-induced neutropenia treatment market.

Which Companies Are Leading in the Chemotherapy-Induced Neutropenia Treatment Market?
Major companies operating in the chemotherapy-induced neutropenia treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GSK plc, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Baxter Inteational, Fresenius Kabi, Eisai Co. Ltd., Dr. Reddy's Laboratories Ltd., Exelixis Inc., Biocon Biologics Limited, Coherus BioSciences Inc., G1 Therapeutics, Enzychem Lifesciences Corporation

What Are the Latest Developing Trends in the Chemotherapy-Induced Neutropenia Treatment Market?
Leading businesses in the market for chemotherapy-induced neutropenia treatment are concentrating on the creation of novel products and winning approvals, such as long-acting formulations. These are designed to improve patient comfort, reduce the number of doses, and increase treatment compliance. Long-acting formulations are drug applications intended to release active substances slowly over a prolonged time, thus decreasing the frequency of administration. For example, in December 2023, the U.S. Food and Drug Administration (FDA) granted approval to Coherus BioSciences Inc., a biopharmaceutical company based in the US, for Udenyca Onbody, an innovative, ready-to-use on-body injector. This apparatus comprising a long-acting formula automatically administers pegfilgrastim approximately 27 hours post chemotherapy, removing the requirement for an injection the following day. Udenyca Onbody improves the patient encounter by ensuring predictive treatment of chemotherapy-induced neutropenia in a timely manner, lessens clinic visits, and augments adherence.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-neutropenia-treatment-global-market-report

What Are the Top Revenue-Generating Geographies in the Chemotherapy-Induced Neutropenia Treatment Market?
North America was the largest region in the chemotherapy-induced neutropenia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced neutropenia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Chemotherapy-Induced Neutropenia Treatment Market?
2. What is the CAGR expected in the Chemotherapy-Induced Neutropenia Treatment Market?
3. What Are the Key Innovations Transforming the Chemotherapy-Induced Neutropenia Treatment Industry?
4. Which Region Is Leading the Chemotherapy-Induced Neutropenia Treatment Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.